Priothera is a late-stage biopharma company, not a technology company in the software or hardware sense, focused on developing mocravimod as an innovative immune modulator for hematologic cancers like acute myeloid leukemia (AML).[1][2][3] It builds an oral adjunctive therapy that enhances the curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) and CAR-T cell therapies by boosting graft-versus-leukemia (GvL) effects while reducing graft-versus-host disease (GvHD) risks, serving AML patients post-transplant and addressing unmet needs in maintenance therapy.[1][2][3] The company, founded in 2020 with headquarters in Dublin and operations in France, is advancing mocravimod in a global Phase IIb/III trial (MO-TRANS) across Europe, the U.S., and Japan as of Q2 2025, backed by investors like Fountain Healthcare Partners, abrdn, and Bpifrance.[1][3]
Priothera's growth momentum includes orphan drug designations from the FDA and EMA, recent €1.7 million i-Nov funding from Bpifrance, and media recognition for its AML work, positioning it to potentially transform standards of care in hematology-oncology.[1][3][5]
Priothera was founded in 2020 by Florent Gros, who serves as CEO, drawing on his expertise to apply mocravimod's established mechanism—previously explored in other contexts—to hematologic malignancies.[1][2][3] The idea emerged from identifying gaps in allo-HCT outcomes, where GvHD limits curative potential despite GvL benefits; Gros's leadership statement highlights mocravimod as a "game-changing treatment" for blood cancers.[2] Early traction came from assembling a management team with deep experience in hematology, oncology, immunology, and cell therapies, securing backing from prominent life sciences investors including Fountain Healthcare Partners, abrdn, EarlyBird Venture Capital, BEI, Bpifrance Grand Est, and the BioInnovation Institute.[1][3] Pivotal moments include launching the MO-TRANS Phase 3 trial and gaining orphan drug status, with operations spanning France (Saint Louis site) and Ireland.[1][3][4]
Priothera rides the wave of advancing cell therapies in oncology, where allo-HCT and CAR-T show curative promise but face GvHD barriers limiting ~30-50% of AML patients' long-term success.[2][3] Timing aligns with surging demand for post-transplant maintenance—AML affects thousands annually with poor survival post-relapse—fueled by regulatory incentives like orphan status and funding (e.g., Bpifrance grants).[3][5] Market forces favoring Priothera include biopharma's shift to immune modulators, rising HCT volumes, and investor interest in late-stage assets amid ~$100B+ global oncology spend.[1][3] It influences the ecosystem by pioneering safer cell therapy combos, potentially setting new standards and enabling broader adoption of high-risk, high-reward transplants.[1][2]
Priothera is poised for Phase 3 readouts from MO-TRANS in the coming years, with positive data potentially accelerating approval and partnerships for commercialization by 2027-2028.[3] Trends like AI-optimized trials, expanded CAR-T indications, and precision hematology will amplify its impact, especially if mocravimod proves scalable across malignancies.[2] Its influence could evolve from niche innovator to standard-of-care leader, transforming AML survival and quality of life—delivering on its "Pursuing More Time For Life" mission amid a biotech funding rebound.[1][2] This positions Priothera as a high-conviction play in hematologic cancer breakthroughs.
Priothera has raised $35.0M in total across 1 funding round.
Priothera's investors include Earlybird Venture Capital, EQT Life Sciences, Forbion, HealthCap, INKEF Capital, Pontifax Venture Capital, Vivo Capital.
Priothera has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series A in October 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2020 | $35.0M Series A | Earlybird Venture Capital, EQT Life Sciences, Forbion, HealthCap, INKEF Capital, Pontifax Venture Capital, Vivo Capital |
